Vital Signs - Healthcare News - The Analysts Perspective - August 2014 Issue

Regular Price: USD 450

Special Price USD 405

10% OFF

* Required Fields

Regular Price: USD 450

Special Price USD 405

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on September 3, 2014, discusses Thermo Fisher Scientific's divestment of laboratory equipment company Cole-Parmer to GTCR, the increasing use of large animal biotechnology in human health applications, the collaboration of Life Technologies and RainTree Oncology Services, the agreement between Ventana and Quintiles to enter the Chinese companion diagnostics market, and the impacts of Thailand's new healthcare policy.

Table of Contents

Vital Signs - Healthcare News - The Analyst's Perspective - August 2014 IssueVital Signs - August 2014This week's issue




Keyword1

Keyword2

Keyword3

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.